Market Update: COP, FIS, FLEX, HES, TT, JNPR, SHEL
​Post Content  Read More
Media
If You Invested $100 In This Stock 15 Years Ago, You Would Have $700 Today
- by
- November 4, 2024
read more ​Â
Media
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
- by
- November 4, 2024
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments. read more ​Â
Media
Bitcoin Can Ignore The Presidential Election As Noise, Says Arthur Hayes
- by
- November 4, 2024
BitMEX co-founder Arthur Hayes opined that the upcoming presidential election is just a distraction from Bitcoin‘s (CRYPTO: BTC) long-term bullish trend. read more ​Â
Media
Broadcom To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday
- by
- November 4, 2024
Latest Ratings for AVGO Date Firm Action From To Mar 2022 Truist Securities Maintains Buy Mar 2022 JP Morgan Maintains Overweight Mar 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for AVGO View the Latest Analyst Ratings read more ​Â
Media
Michigan Pension Fund Invests $10M In Ethereum ETFs, Exceeds Bitcoin Holdings
- by
- November 4, 2024
The Michigan State Pension Fund has invested $10 million in Grayscale’s Ethereum ETFs (NYSE:ETHE), making it one of the top holders of the product. read more ​Â
Media
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
- by
- November 4, 2024
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG’s Treg-focused action as a potential breakthrough for Alopecia areata treatment. Latest Ratings for NKTR Date Firm Action From To Mar 2022 Oppenheimer Upgrades Perform Outperform Nov 2021 Benchmark Upgrades Hold Buy Nov 2021 SVB Leerink Maintains Market Perform View More Analyst Ratings for NKTR View the
Media
This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
- by
- November 4, 2024
Latest Ratings for BAH Date Firm Action From To Mar 2022 B of A Securities Upgrades Underperform Neutral Feb 2022 Morgan Stanley Maintains Overweight Jan 2022 B of A Securities Downgrades Buy Underperform View More Analyst Ratings for BAH View the Latest Analyst Ratings read more ​Â